Tobramycin Sulfate

CHEMBL3989564 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1425.4 g/mol

LogP

—

Phase

4

A sulfate salt form of tobramycin with the same therapeutic properties. This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection).

Molekularmasse

1425,4000 g/mol

TPSA

951,00 Å²

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Chronic Kidney Disease Hypertension Breast Cancer Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O.NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O

InChI

InChI=1S/2C18H37N5O9.5H2O4S/c2*19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;5*1-5(2,3)4/h2*5-18,24-28H,1-4,19-23H2;5*(H2,1,2,3,4)/t2*5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;;;;;/m00...../s1

Molecular Formula

C36H84N10O38S5

HBD / HBA

30 / 48

Rotierbare Bindungen

12

Schwere Atome

89

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A sulfate salt form of tobramycin with the same therapeutic properties. This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection).

Yes, Tobramycin Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989564. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11954252. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Tobramycin Sulfate auf PillFYI

Struktur

Schnelldaten

Formel: C36H84N10O38S5
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.